Oruka Therapeutics, Inc.

For the period ended Mar 31, 2026. Filed May 13, 2026.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Mar 31, 2026 · Filed May 13, 2026

ORKA$109.50+4.7%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Statements of Operations

(In thousands, except share and per share data)

	Three Months Ended March 31, 2026	Three Months Ended March 31, 2025
Operating expenses:
Research and development(1)	$29,145	$19,925
General and administrative(2)	7,289	5,161
Total operating expenses	36,434	25,086
Loss from operations	(36,434)	(25,086)
Other income (expense):
Interest income	4,606	4,092
Other income (expense), net	8	(5)
Total other income, net	4,614	4,087
Net loss	$(31,820)	$(20,999)
Net loss per share attributable to common stockholders, basic and diluted	$(0.48)	$(0.40)
Net loss per share attributable to Series B non-voting convertible preferred stockholders, basic and diluted	$(39.81)	$(32.95)
Weighted-average shares used in computing net loss per share attributable to common stockholders, basic and diluted	55,172,410	41,679,560
Weighted-average shares used in computing net loss per share attributable to Series B non-voting convertible preferred stockholders, basic and diluted	137,138	137,138

(1)	Includes related party amounts of $3,000 and $2,122 for the three months ended March 31, 2026 and 2025, respectively

(2)	Includes related party amounts of $4 and $110 for the three months ended March 31, 2026 and 2025, respectively

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.